Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 794 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Quince Therapeutics, Inc.
Market Cap
$7.66M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.40M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.93M
Net Profit Margin
0.00%
TTM Avg
-431.21%
3Y Avg
-828.00%
5Y Avg
-552.00%
Market Cap
$7.95M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.96M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.95M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.31M
Net Profit Margin
-0.61%
TTM Avg
-82.77%
3Y Avg
-131.16%
5Y Avg
-372.00%
Market Cap
$7.27M
Net Profit Margin
-1977.59%
TTM Avg
-1280.67%
3Y Avg
-1780.71%
5Y Avg
-1415.68%
Market Cap
$7.09M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-287.91%
5Y Avg
-676.70%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | $7.66M | 0.00% | 0.00% | 0.00% | 0.00% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.40M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.93M | 0.00% | -431.21% | -828.00% | -552.00% |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.95M | 0.00% | 0.00% | 0.00% | 0.00% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.96M | 0.00% | 0.00% | 0.00% | 0.00% |
| GT Biopharma, Inc. (GTBP)vs › | $7.95M | 0.00% | 0.00% | 0.00% | 0.00% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | -0.61% | -82.77% | -131.16% | -372.00% |
| Longeveron Inc. (LGVN)vs › | $7.27M | -1977.59% | -1280.67% | -1780.71% | -1415.68% |
| KALA BIO, Inc. (KALA)vs › | $7.09M | 0.00% | 0.00% | -287.91% | -676.70% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.08M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
